ImaRx's SonoLysis Enters Phase I/II Trial in PAOD

ImaRx Therapeutics announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of SonoLysis for the treatment of peripheral arterial occlusive disease (PAOD). SonoLysis, which combines external ultrasound and ImaRx's proprietary nanobubbles, is designed to clear blood clots quickly and without the use of invasive surgery or potentially dangerous lytic drugs.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=498915XSL_NEWSML_TO_NEWSML_WEB.xml)